Halozyme Therapeutics, Inc. (HALO)
Nasdaq · Healthcare · Biotechnology
$108.31−1.41%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $12.3B
- P/E (trailing)
- 31.7
- Forward P/E
- 10.4
- 52-week range
- $61.23 – $116.85
- 52-week change
- +66.40%
- EPS (trailing)
- $3.42
- Next earnings
- Nov 2, 2026
Fiscal year to Dec 2025
- Revenue
- $1.4B (+37.56%)
- Net income
- $317M
- Operating margin
- 33.6%
- Diluted EPS
- $2.56
- Free cash flow
- $645M
From the company’s annual report on SEC EDGAR.
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy.
Headquarters: San Diego, United States · 423 employees · halozyme.com